公开(公告)号：US20230052212A1

公开(公告)日：2023-02-16

申请号：US17818256

申请日：2022-08-08

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Kristen PIERCE ,  Janine POWERS ,  Servando PALENCIA ,  Robert SIKORSKI ,  Majid GHODDUSI ,  Kartik KRISHNAN

IPC: C07K16/28 ,  G01N33/50 ,  G01N33/574 ,  C07K16/30

Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.

公开(公告)号：US20180147271A1

公开(公告)日：2018-05-31

申请号：US15575220

申请日：2016-05-17

Applicant: bluebird bio, Inc. ,  Five Prime Therapeutics, Inc. ,  Eureka Therapeutics, Inc.

Inventor： Richard MORGAN ,  Robert SIKORSKI ,  Brian WONG ,  Emma MASTELLER ,  Luis BORGES ,  Cheng LIU ,  Yiyang XU

IPC: A61K39/00 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  A61P35/02

CPC classification number: A61K39/0011 ,  A61K2039/505 ,  A61P35/02 ,  C07K14/7051 ,  C07K16/2803 ,  C07K16/30 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/03 ,  C07K2319/74

Abstract: The invention provides improved compositions for adoptive cell therapies for cancers that express ROR1.